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bat the global epidemic of human 
immunodeficiency virus (HIV) in-
fection. Thus was launched one 
of the largest international health-
assistance programs in history. 
PEPFAR has since been both con-
demned as unilateral, paternal-
istic, narrowly focused, and dis-
torted by a political agenda and 
lauded as groundbreaking, vision-
ary, effective, and responsible for 
saving hundreds of thousands of 
lives. This year, Congress has 
had to consider the reauthoriza-
tion of the program. On July 16, 
the Senate approved legislation 
that would increase the funding 
to $48 billion for the next 5 years, 
sending the measure into confer-
ence committee. Thus, this seems 
an appropriate time to examine 
PEPFAR’s achievements, limitations, 
and lessons for the future.
The HIV epidemic had been 
raging for more than two de-
cades before the establishment of 
PEPFAR. For much of this time, 
the millions of HIV-infected people 
in resource-limited countries had 
little access to effective treatment. 
Instead, the response had focused 
almost exclusively on behavior-
changing strategies to prevent HIV 
transmission. Yet in wealthier 
countries, antiretroviral treatment 
was becoming increasingly effec-
tive in reducing morbidity and 
mortality, and in 2004, the global 
gap in access to treatment was 
starkly highlighted at the Inter-
national AIDS Conference in Bang-
kok. At a time when only 50,000 
Africans (1% of the estimated 
4.4 million in need) were receiv-
ing antiretroviral drugs, the con-
ference’s theme of “Access for All” 
became the rallying cry for the 
global HIV community.1 PEPFAR 
was part of the response to this 
emergency, meant to confront the 
epidemic that was causing inde-
scribable suffering and destroying 
the fabric of communities around 
the world.
Since its inception, PEPFAR has 
faced criticism. Its most vocal crit-
ics have focused on some of its 
prevention strategies, which they 
view as driven by ideology rather 
than science. These include the 
overemphasis on abstinence as a 
key approach to risk reduction, the 
prohibition on support for com-
mercial sex workers, and the op-
position to needle and syringe ex-
change for injection-drug users.
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But critics have also questioned 
PEPFAR’s focus on HIV care and 
treatment. From the beginning, 
concerns have been raised regard-
ing the feasibility and wisdom 
of expanding HIV treatment wide-
ly in resource-limited countries. 
Treatment was thought to be too 
complex, requiring management 
by physicians, who are scarce in 
these countries. For example, in 
Mozambique, which has an HIV 
prevalence of 16% among adults 
and an annual per capita health 
expenditure of $47, there are only 
3 physicians per 100,000 inhab-
itants.2 It was also feared that 
crumbling health care facilities 
would fail to cope with a greatly 
increased demand for services and 
that the absence of functioning 
laboratories would jeopardize the 
lives of patients who did receive 
treatment. Weak systems for phar-
maceutical and commodity pro-
curement with histories of gaps 
in availability were considered un-
likely to deliver a secure drug sup-
ply. Some feared that reliance on 
generic antiretroviral drugs would 
lead to the use of low-quality 
knockoffs. Stigma was thought to 
present an insurmountable barrier 
that would inhibit patients from 
seeking treatment. It was also as-
sumed that the requisite level of 
adherence to therapy was unlikely 
to be attained by poor people who 
had little experience with long-
term medical care. Critics paint-
ed vivid images of drug-resistant 
HIV strains raging first through 
Africa and then throughout the 
world.
PEPFAR was also criticized for 
creating a vertical program with 
disease-specific goals, as well as 
a single-donor–driven structure 
and strategy, which some observ-
ers saw as threatening to under-
mine both national AIDS-control 
programs and the multilateral, 
multidonor Global Fund to Fight 
AIDS, Tuberculosis, and Malaria.
Given these reservations, how 
well has the program done? As 
of the end of March 2008, as a re-
sult of contributions by PEPFAR, a 
total of 1.7 million people had re-
ceived antiretroviral therapy3 — 
reflecting an expansion of access 
to treatment by a factor of more 
than 10 in less than 4 years. 
Despite its verticality, the pro-
gram has also been reasonably well 
integrat ed with the global and na-
tional responses to the HIV epi-
demic. PEPFAR has collaborated 
with national AIDS-control pro-
grams in endorsing the approach 
of the World Health Organization, 
which recommends that each 
country have a single national HIV 
strategy, a single national treat-
ment guideline, and a single frame-
work for monitoring and evalua-
tion. In most of the 15 countries 
where PEPFAR has focused its ef-
forts, donors and host govern-
ments participate in multisectoral 
planning to ensure that donor 
funding complements the nation-
al AIDS-control strategy. 
This effort has often revitalized 
national AIDS responses and may 
inspire similar coordination in re-
lation to other health and devel-
opment programs. Increasingly, 
PEPFAR funding is also support-
ing HIV treatment services be-
yond those provided by referral 
hospitals, including at district hos-
pitals and primary health care cen-
ters, where most people receive 
care and where HIV services are 
by necessity integrated into pri-
mary care services.
The effect on the wider health 
care system of funding a disease-
specific program is harder to 
quantify. HIV disease, a chronic 
condition requiring follow-up dur-
ing periods of health and illness, 
has motivated the establishment 
of systems to ensure continuity of 
care. Such systems are needed for 
the effective management of other 
chronic conditions, such as dia-
betes, cardiovascular disease, and 
mental illness. Funding from 
PEPFAR has contributed to en-
hanced support for pharmacies 
and laboratories and has spurred 
substantial growth of community-
based patient-support programs 
— services that may benefit broad 
populations of patients. More-
over, it has promoted the em-
powerment of persons living with 
HIV through the support of peer-
education programs led by HIV-
infected persons, which may have 
positive implications for creating 
health care systems that pay at-
tention to the needs and priori-
ties of patients and draw on their 
insights into program design and 
implementation.4 The types of 
programs eligible for PEPFAR 
funding have expanded to include 
services such as those for tuber-
culosis and malaria, two condi-
tions highly relevant to HIV dis-
ease. There has also been support 
for the training of a wide array of 
health care providers, which may 
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bring broad benefits to health care 
systems.
Despite PEPFAR’s achievements, 
however, some critics argue that 
the program has fallen short in 
fundamental ways: it has not sub-
stantially altered the landscape 
in terms of stigma against peo-
ple with HIV, inequity between 
the sexes, environmental threats 
to health, lack of educational op-
portunities for young people, and 
policies that restrict the expan-
sion of the health care workforce. 
Such concerns suggest that it may 
be time for PEPFAR to transform 
itself from an emergency plan 
largely focused on preventing and 
treating HIV infection to one that 
aims to strengthen health care 
systems in general and to address 
root causes of the HIV epidemic, 
including social and economic 
factors. 
In a sense, then, the key 
choice for PEPFAR at this cross-
roads is between a “pull” strategy 
and a “push” strategy: Will a con-
tinued singular focus on HIV “pull” 
other components of national 
health care systems forward, so 
that they become more responsive 
to other health threats and can 
catalyze the necessary changes in 
social norms and policy? Or will 
a “push” strategy that is focused 
primarily on strengthening health 
care systems and tackling funda-
mental issues that define societal 
vulnerabilities to disease be more 
effective in achieving both HIV-
specific and broader health and 
social goals?
Historically, strategies for con-
trolling epidemics have ranged 
from treating diseases and pre-
venting infections to addressing 
the environmental, social, attitu-
dinal, and policy-related factors 
fueling the epidemic. An analysis 
of the history of epidemics in New 
York City, for example, noted that 
the decrease in their occurrence 
during the latter part of the 19th 
century was largely due to the 
implementation of fundamental 
changes in the city environment, 
combined with new public health 
policies.5
However, these approaches may 
be erroneously perceived as di-
chotomous. Epidemics first re-
quire rapid action and concerted 
efforts to alleviate suffering — 
making PEPFAR’s early prioriti-
zation of treatment appropriate 
and humane. At this point in its 
evolution, there are loud calls for 
PEPFAR to pay greater attention 
to supporting overall health care 
systems and to addressing soci-
etal vulnerabilities to HIV. Yet the 
emergency is far from over. De-
spite heroic efforts, only 37% of 
the estimated number of people 
in need of treatment in the 15 
PEPFAR focus countries are re-
ceiving such treatment.3 Although 
efforts to address underlying sys-
temic problems are legitimate, in-
tensive work is still necessary to 
expeditiously reach millions of 
people with HIV infection, and 
considerable work is needed to 
achieve HIV prevention goals.
The key challenge for PEPFAR 
will be to maintain its sense of 
urgency and its razor-sharp focus 
on results — factors that have 
resulted in remarkable achieve-
ments in the face of enormous 
challenges. The advances have 
been dramatic, but much remains 
to be done.
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